-
S&P Analyst: Here's What Matters Most To Apple Next Week
Saturday, April 23, 2016 - 9:03am | 338Read More...Apple Inc. (NASDAQ: AAPL) is expected to have "by far the most difficult quarter" for iPhone shipments on year-over-year basis when it reports its second-quarter results on April 26, Angelo Zino of S&P Global Market Intelligence told CNBC. Zino, who has a Buy rating on Apple, expects a shipment...
-
Anheuser-Busch InBev: Future M&A Potential?
Friday, April 22, 2016 - 2:50pm | 861Read More...Anheuser Busch Inbev SA (ADR) (NYSE: BUD) may look at potential M&A opportunities to achieve its long-term target of $100 billion revenue by 2020, according to a note from Bernstein analyst Trevor Stirling. According to a Form 20-F, the company's "Dream 2020" plan calls for revenues of $100...
-
Why You Should Buy Any Weakness After Visa's Q1 Report
Friday, April 22, 2016 - 9:41am | 555Read More...Shares of Visa Inc (NYSE: V) extended its losses from Thursday as it fell about 4 percent in the pre-market hours after the payments network firm cut its full-year revenue outlook on low cross-border spending. But, a Goldman Sachs analyst suggests that investors should cash in on any weakness in...
-
Stephens Calls Ligand 'Unique,' Sees $150/Share Coming By 2017
Wednesday, April 13, 2016 - 9:33am | 519Read More...Ligand Pharmaceuticals Inc. (NASDAQ: LGND) is a unique biotech play that offers long-term staged growth profile, according to a note from Stephens, which initiated coverage of the stock with an Overweight (Volatile) rating. The brokerage has $150 price target on the stock, representing an upside of...
-
Taking The Plunge On Vera Bradley: Should You?
Thursday, March 24, 2016 - 2:55pm | 426Read More...Wunderlich Securities has upgraded handbag maker Vera Bradley, Inc. (NASDAQ: VRA) to Buy from Hold and raised its price target to $24 from $15. Subsequently, the stock jumped roughly 7 percent. "We believe the company is nearing the next major round of upside catalysts which will amply demonstrate...
-
Top Analyst Bullish On Salesforce.com Following Record Quarter
Thursday, February 25, 2016 - 4:22pm | 434Read More...salesforce.com, inc. (NYSE: CRM) reported record earnings this morning, marked by unprecedented growth and favorable operating margin. As a result of promising trends, top analyst Brian Schwartz of Oppenheimer believes the stock is destined for growth. This morning, Schwartz reiterated an...
-
Why Are Analysts So Bullish On This Tumbling Biotech Company?
Monday, February 8, 2016 - 11:32am | 676Read More...In the past month, shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) have plummeted more than 45 percent. Granted that the biotech sector has been off to a rough start in 2016, but this 45 percent is staggering in comparison to SPDR biotech ETF, XBI, which fell 24 percent in the same period....
-
This Video Game Company May Be Surging After Earnings, But A Top Analyst Warns Not To Buy The Hype
Thursday, February 4, 2016 - 6:36pm | 515Read More...Aside from being an obsession for many, the video game business has blossomed into a multi-billion dollar industry that many are eager to join. Despite the hype, top analyst Colin Sebastian of Robert W. Baird urges investors to stay on the sidelines of Take-Two Interactive Software, Inc. (...
-
Bearish Apple Analyst Fired
Tuesday, December 29, 2015 - 1:39pm | 597Read More...By Sarah Roden. This article does not represent the opinion of Benzinga. Apple Inc. (NASDAQ:AAPL) is debatably the most popular stock on the market. The hegemonic technology company has nestled its way into every aspect of life, from cell phones, to TV, to music. Who would dare say the stock...
-
The Top 20 Wall Street Analysts Of 2015
Thursday, December 17, 2015 - 11:44am | 3452Read More...TipRanks gathers analyst ratings and ranks them based on accuracy over time. Here is a list of the top 20 Wall Street analysts of 2015, according to the platform's data. 1. Irina Rivkind Koffler Mizuho Securities 103 out of 148 successful ratings (70 percent) Irina Rivkind Koffler...
-
Goldman Sachs, Pepco, Walgreens Boots Alliance, E*TRADE Lead Wednesday's Top Ratings Changes
Wednesday, September 9, 2015 - 12:11pm | 744Read More...There has been a lot of action on Wall Street today as analysts have weighed in on their favorite stocks. Below are the most notable analyst upgrades and downgrades: Goldman Sachs Group Inc Michael Carrier of Bank of America/Merrill Lynch upgraded his rating on Goldman Sachs Group Inc (NYSE:...
-
MannKind, Keryx Bio, Transocean Lead Monday's Early Movers
Monday, August 10, 2015 - 9:42am | 756Read More...MannKind Corporation (NASDAQ:MNKD) shares spiked 6.28% in pre-market trading to $4.23 after the biopharmaceutical company posted second quarter earnings. MannKind posted a net loss of $(0.07) per share, slightly narrower than the analyst estimate of $(0.08) and marking an improvement from $(...
-
FMC President Buys $1M In Stock Day After Street Targets Cut
Friday, July 24, 2015 - 11:37am | 496Read More...Shares of FMC Technologies, Inc. (NYSE: FTI) tumbled on Wednesday after the company reported that earned $0.46 in its second quarter, short of the $0.61 per share analysts were expecting while revenue of $1.7 billion fell slightly short of the $1.71 billion analysts were estimating. In a report...
-
What BlackBerry, Micron And Darden Investors Can Expect This Week
Monday, June 22, 2015 - 11:01am | 910Read More...The new earnings season is on the cusp of starting up again with three big names reporting earnings this week. Find out what to watch for in Blackberry Ltd (NASDAQ: BBRY), Micron Technology, Inc. (NASDAQ: MU) and Darden Restaurants, Inc. (NYSE: DRI): Blackberry Mobile phone company Blackberry...
-
Needham: Aerie Pharma's FDA Agreement 'Re-Establishes A Clinical Path Forward' For Rhopressa
Tuesday, June 16, 2015 - 11:55am | 383Read More...Aerie Pharmaceuticals Inc (NASDAQ: AERI) has created a lot of buzz this morning as shares jumped 56 percent in pre-market trading following news that the FDA has allowed the company to modify the primary endpoint of its second Phase 3 trial of Rhopressa; an eye drop that alleviates intraocular...
